Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CLA CVE:EMH NYSEARCA:GSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLAColonnade Acquisition$25.04$12.38$9.54▼$17.73$625.93MN/A1.35 million shs3,800 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsGSPiPath S&P GSCI Total Return Index ETN$19.66$19.65$18.19▼$28.75$21.84MN/A3,679 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLAColonnade Acquisition0.00%0.00%0.00%0.00%0.00%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%GSPiPath S&P GSCI Total Return Index ETN0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLAColonnade AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGSPiPath S&P GSCI Total Return Index ETNN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLAColonnade Acquisition 0.00N/AN/AN/AEMHEmerald Health Therapeutics 0.00N/AN/AN/AGSPiPath S&P GSCI Total Return Index ETN 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLAColonnade AcquisitionN/AN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64GSPiPath S&P GSCI Total Return Index ETNN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLAColonnade AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AGSPiPath S&P GSCI Total Return Index ETNN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLAColonnade AcquisitionN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AGSPiPath S&P GSCI Total Return Index ETNN/A0.00%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLAColonnade AcquisitionN/A14.6514.65EMHEmerald Health Therapeutics35.452.972.61GSPiPath S&P GSCI Total Return Index ETNN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLAColonnade AcquisitionN/AEMHEmerald Health TherapeuticsN/AGSPiPath S&P GSCI Total Return Index ETNN/AInsider OwnershipCompanyInsider OwnershipCLAColonnade AcquisitionN/AEMHEmerald Health TherapeuticsN/AGSPiPath S&P GSCI Total Return Index ETNN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLAColonnade AcquisitionN/A25.00 millionN/ANot OptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableGSPiPath S&P GSCI Total Return Index ETN2,0201.11 millionN/ANot OptionableCLA, EMH, ZNWD, and GSP HeadlinesRecent News About These CompaniesiPath® S&P GSCI® Crude Oil Total Return Index ETN (OIL_OLD)June 27, 2025 | investing.comGSP Resource Corp. Announces Private Placement FinancingMarch 17, 2025 | thenewswire.comTGSP Defines New Porphyry Copper Drill Targets and Prepares to Submit Drill Permit Application for Mer PropertyMarch 13, 2025 | thenewswire.comTGSP Resource Corp. Invites Shareholders and Investment Community to visit us at Booth 305 at the VRIC in Vancouver, January 19-20, 2025January 15, 2025 | newsfilecorp.comNS&P MERVAL IndexOctober 19, 2024 | wsj.comQE Total Return (QETR)September 1, 2024 | investing.comBarclays iPath(R) Exchange Traded Notes Scheduled to Move to NYSE ArcaAugust 19, 2024 | br.advfn.comCompare with S&P GSCI Light Energy Index (CPW 4) Total Return (G75)May 28, 2024 | msn.comOBX Total Return Index (OBX.OL)May 25, 2024 | finance.yahoo.comHere Are 2 Remarkable Growth Stocks to Own Right NowMarch 29, 2024 | theglobeandmail.comSPGSHO S&P GSCI Heating Oil Index SpotDecember 28, 2023 | seekingalpha.comSGECASP S&P GSCI Agriculture Enhanced Select Index Spot Excess ReturnNovember 22, 2023 | seekingalpha.com2023 ETF Stock Price HistoryNovember 18, 2023 | investing.comGSP ETF Stock Price HistoryNovember 18, 2023 | investing.comOBX Uncapped Total Return (OBXU)October 9, 2023 | uk.investing.comS&P-GSCI Excess Return Index Jan 2024September 24, 2023 | barrons.comSP500-5510TR S&P 500 Utilities Index Industry Group - Total ReturnSeptember 14, 2023 | seekingalpha.comiPath S&P GSCI Crude Oil Total ReturnSeptember 3, 2023 | investing.comSPGSPAP S&P GSCI Palladium Index Excess ReturnAugust 26, 2023 | seekingalpha.comFed's 2022 rate hikes haven't 'fully worked itself into the system': StrategistJuly 25, 2023 | finance.yahoo.com Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]By MarketBeat Staff | July 29, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025Grab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025CLA, EMH, ZNWD, and GSP Company DescriptionsColonnade Acquisition NYSE:CLAColonnade Acquisition Corp. is a blank check company that acquires assets and businesses through a merger, share exchange, share purchase, reorganization, and similar business combination. The company was founded in 2020 and is based in West Palm Beach, FloridaEmerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.iPath S&P GSCI Total Return Index ETN NYSEARCA:GSP$19.66 0.00 (0.00%) As of 06/14/2023 More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Reynolds Consumer Products Stock Price: Insiders Signal a Bottom Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a Trend Southern Company: From Nuclear Risk to AI Reward BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock Time for Cleveland-Cliffs Stock to Break Out? Markets Say Yes As the Market Rotates, This Healthcare ETF Is Leading the Way Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access